Amoxicillin/clavulanic acid-warfarin drug interaction: A randomized controlled trial

British Journal of Clinical Pharmacology

Volumn 71, Issue 2, 2011, Pages 232-236

  Zhang, Qian ^a   Simoneau, Guy ^a   Verstuyft, Celine ^b   Drouet, Ludovic ^a   Bal Dit Sollier, Claire ^a   Alvarez, Jean Claude ^c   Rizzo Padoin, Nathalie ^a   Bergmann, Jean Francois ^a   Becquemont, Laurent ^b   Mouly, Stéphane ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

Amoxicillin clavulanic acid; Drug interaction; Infection; Inflammation; Warfarin

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; PLACEBO; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL ARTICLE; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 78650977894     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03824.x     Document Type: Article

References (21)

1. Angaran DM, Dias VC, Arom KV, Northrup WF, Kersten TG, Lindsay WG, Nicoloff DM. The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient. Cefamandole, cefazolin, vancomycin. Ann Surg 1987; 206: 155-61.
2. Kawamoto K, Touchi A, Sugeno K, Matsubara T. In vitro effect of beta-lactam antibiotics and N-methyltetrazolethiol on microsomal vitamin K epoxide reductase in rats. Jpn J Pharmacol 1988; 47: 169-78.
3. MICROMEDIX. Available at (last accessed 10 August 2007).
4. Schelleman H, Bilker WB, Brensinger CM, Han X, Kimmel SE, Hennessy S. Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding. Clin Pharmacol Ther 2008; 84: 581-8.
5. Fischer HD, Juurlink DN, Mamdani MM, Kopp A, Laupacis A. Hemorrhage during warfarin therapy associated with cotrimoxazole and other urinary tract anti-infective agents: a population-based study. Arch Intern Med 2010; 170: 617-21.
6. Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R. Main comedications associated with major bleeding during anticoagulant therapy with coumarins. Eur J Clin Pharmacol 2005; 61: 439-44.
7. Davydov L, Yermolnik M, Cuni LJ. Warfarin and amoxicillin/clavulanate drug interaction. Ann Pharmacother 2003; 37: 367-70.
8. Kelly M, Moran J, Byrne S. Formation of rectus sheath hematoma with antibiotic use and warfarin therapy: a case report. Am J Geriatr Pharmacother 2005; 3: 266-9.
9. Conly J, Stein K. Reduction of vitamin K2 concentrations in human liver associated with the use of broad spectrum antimicrobials. Clin Invest Med 1994; 17: 531-9.
10. Renton KW. Cytochrome P450 regulation and drug biotransformation during inflammation and infection. Curr Drug Metab 2004; 5: 235-43.
11. Freedman MD, Olatidoye AG. Clinically significant drug interactions with the oral anticoagulants. Drug Saf 1994; 10: 381-94.
12. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 23: 1095-106.
13. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106: 2329-33.
14. Larramendy-Gozalo C, Yang JQ, Verstuyft C, Bodin L, Dubert L, Zhang Y, Xu C, Fan L, Jaillon P, Becquemont L. Genetic polymorphism of vitamin K epoxide reductase (VKORC1) 1173C>T in a Chinese and a Caucasian population. Basic Clin Pharmacol Toxicol 2006; 98: 611-3.
15. Niopas I, Toon S, Aarons L, Rowland M. The effect of cimetidine on the steady-state pharmacokinetics and pharmacodynamics of warfarin in humans. Eur J Clin Pharmacol 1999; 55: 399-404.
16. Mahé I, Bertrand N, Drouet L, Bal Dit Sollier C, Simoneau G, Mazoyer E, Caulin C, Bergmann JF. Interaction between paracetamol and warfarin in patients: a double-blind, placebo-controlled, randomized study. Haematologica 2006; 91: 1621-7.
17. Obayashi K, Nakamura K, Kawana J, Ogata H, Hanada K, Kurabayashi M, Hasegawa A, Yamamoto K, Horiuchi R. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients. Clin Pharmacol Ther 2006; 169-78.
18. Augmentin® 500/62, 5 mg [Dose Package Insert]. Marly-le-Roi, France. GlaxoSmithkline 2006.
19. Aitken AE, Richardson TA, Morgan ET. Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol 2006; 46: 123-49.
20. Lang CC, Brown RM, Kinirons MT, Deathridge MA, Guengerich FP, Kelleher D, O'Briain DS, Ghishan FK, Wood AJ. Decreased intestinal CYP3A4 in celiac disease: reversal after successful gluten-free diet: a potential source of interindividual variability in first-pass metabolism. Clin Pharmacol Ther 1996; 59: 41-6.
21. Bleau AM, Fradette C, El-Kadi AOS, Cote MC, Du Souich P. Cytochrome P450 down-regulation by serum from humans with a viral infection and from rabbits with an inflammatory reaction. Drug Metab Dispos 2001; 29: 1007-12.